Amendment: Correction of ISIN in prospectus
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS.
The ISIN for the interim shares (Sw: betald tecknad aktie, BTA) and the subscription rights (Sw: teckningsrätt, TR) in the prospectus regarding Vigmed Holding AB’s (publ) (“Vigmed” or the “Company”) rights issue has been interchanged. The correct information for each security is listed below:
ISIN share: SE0005034576
ISIN interim share (BTA): SE0007730601
ISIN subscription right (teckningsrätt): SE0007730593
For more information, please contact:
Henrik Olsen, CEO Vigmed, telephone +46 763 49 73 64, e-mail email@example.com or Lennart Holm, Chairman of the Board, telephone +46 706 30 85 62.
Vigmed discloses the information in this press release pursuant to the Swedish Securities Markets Act.
The information was provided for public release on 24 November 2015 at 08:00 CET.
This press release is not an offer regarding shares or other securities issued by Vigmed Holding AB (publ) (“Vigmed” or the “Company”).
This press release may not be distributed in or into the United States, Canada, Japan, Australia or in any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law. Nor may the information in this press release be forwarded or reproduced in a manner that contravenes such restrictions or gives cause to such requirements.
No securities issued by the Company have been or will be registered under the United States Securities Act of 1933, as amended (“Securities Act”) and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act. No public offering will be made in the United States.
In member states within the European Economic Area (EEA) (other than Sweden) which have implemented Directive 2003/71/EC (the “Prospectus Directive”), this press release is directed only at qualified investors as defined in the Prospectus Directive.
This press release may contain certain forward-looking statements that reflect the Company’s current views on future events as well as financial and operational performance. Words such as “intend”, “assess”, “expect”, “may”, “plan”, “believe”, “estimate” and other expressions entailing indications or predictions of future development or trends, and which are not based on historical facts, constitute forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements information is not a guarantee of future results or performance, and the actual outcome may differ materially from the information set forth in the forward-looking statements.
A prospectus prepared in accordance with the Prospectus Directive have been published on 20 November 2015 and is, with certain restrictions, available at www.vigmed.com.
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 500 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor